This article was originally published in The Gray Sheet
Plans to file an appeal "in the near future" against de-listing proceedings initiated by the American Stock Exchange, the firm reports. Due to the firm's "history of losses and other related factors, the company continues to be below certain guidelines for continuing listing of its common stock on the exchange," Oncor explains. The Gaithersburg, Maryland maker of gene-based cancer test systems is seeking to "recapitalize its capital structure through the infusion of additional capital" to enhance its financial position
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.